Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
The University of North Carolina, Chapel Hill National Institutes of Health (NIH) |
---|---|
Information provided by: | The University of North Carolina, Chapel Hill |
ClinicalTrials.gov Identifier: | NCT00766818 |
In this study, we are looking at blood concentrations of Kaletra in HIV positive patients during pregnancy. The patients will come in for 4 visits lasting ~24hrs. These visits take place at 20-24 weeks, 30 weeks, 32 weeks and 8 weeks post-partum. At the end of vist 2 (week 30), we will increase your dose to 2 adult Kaletra tablets, and one pediatric Kaletra tablet (total dose 500/125mg). The dose will remain increased until you are 2 weeks post partum, then it will return to the standard 2 adult tablets (400/100mg).
Condition | Intervention | Phase |
---|---|---|
Pregnancy HIV |
Drug: Kaletra |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Pharmacokinetics Study |
Official Title: | The Effect of Pregnancy on the Pharmacokinetics of the Kaletra Tablet: A Longitudinal Investigation in the Second and Third Trimesters Including Empiric Dosage Adjustment |
Estimated Enrollment: | 12 |
Study Start Date: | January 2007 |
Estimated Study Completion Date: | January 2010 |
Estimated Primary Completion Date: | January 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Kaletra
|
Drug: Kaletra
Kaletra 400/100mg BID, then increase at 30weeks to 500/125mg BID
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Amanda E Jones, PharmD | 919-843-8723 | amanda_jones@unc.edu |
United States, North Carolina | |
University of North Carolina | Recruiting |
Chapel Hill, North Carolina, United States, 27599 | |
Contact: Amanda E Jones, PharmD 919-843-8723 amanda_jones@unc.edu | |
Principal Investigator: Kristine Patterson, MD | |
Principal Investigator: Angela DM Kashuba, PharmD |
Principal Investigator: | Angela DM Kashuba, PharmD | University of North Carolina |
Principal Investigator: | Kristine B Patterson, MD | University of North Carolina |
Responsible Party: | University of North Carolina ( Angela Kashuba, PharmD and Kris Patterson,MD ) |
Study ID Numbers: | IRB #06-0653 |
Study First Received: | October 3, 2008 |
Last Updated: | October 9, 2008 |
ClinicalTrials.gov Identifier: | NCT00766818 |
Health Authority: | United States: Food and Drug Administration; United States: Institutional Review Board |
Lopinavir HIV Infections Acquired Immunodeficiency Syndrome |
Anti-Infective Agents HIV Protease Inhibitors Anti-HIV Agents Anti-Retroviral Agents Molecular Mechanisms of Pharmacological Action |
Therapeutic Uses Enzyme Inhibitors Antiviral Agents Pharmacologic Actions Protease Inhibitors |